Cystic Fibrosis Patients on Triple-Drug Therapy Can Safely Reduce Daily Lung Treatments, Multi-Site Study Shows
核心洞察
A multi-site study of over 600 cystic fibrosis patients found that those on elexacaftor/tezacaftor/ivacaftor (ETI (搜索)) triple-drug therapy can safely reduce many daily lung treatments while maintaining good health for years.
Teens and adults cut their use of chronic respiratory therapies by nearly half, with younger children showing similar trends, without experiencing loss of lung function or increased respiratory symptoms.
The findings suggest a significant reduction in treatment burden for CF patients, potentially improving quality of life while maintaining clinical outcomes through personalized care decisions.
A groundbreaking multi-site study led by researchers at CU Anschutz (搜索) demonstrates that people with cystic fibrosis (CF) who begin triple-drug therapy with elexacaftor/tezacaftor/ivacaftor (ETI (搜索)) can safely reduce many of their daily lung treatments while maintaining good health for years. The research, published in the Journal of Cystic Fibrosis, offers hope for significantly reducing the treatment burden that has defined CF care for decades.
Substantial Reduction in Daily Respiratory Therapies
The study followed more than 600 children and adults after they began ETI (搜索) treatment. Children ages 6 to 11 were tracked for up to three years, while adolescents and adults were followed for up to four and a half years. Across all age groups, use of chronic respiratory therapies including hypertonic saline (搜索), dornase alfa, inhaled antibiotics and oral azithromycin fell steadily over time.
The results were striking: teens and adults cut their use of these treatments by nearly half, with younger children showing similar trends. This represents a dramatic shift in CF management, as patients have traditionally spent hours every day managing their disease through multiple respiratory therapies.
"This is incredibly meaningful for individuals and families living with CF," said lead author Scott Sagel, MD, PhD, professor of pediatrics-pulmonary medicine at the CU Anschutz (搜索) School of Medicine and director of the University of Colorado Cystic Fibrosis Center (搜索). "For decades people with CF have spent hours every day managing their disease. Our findings show that many have stepped back from some of those time-consuming therapies thanks to ETI (搜索)."
Maintained Lung Function Despite Reduced Treatment
A key finding was that stopping multiple daily therapies did not appear to lead to loss of lung function or more respiratory symptoms. This held true across age, sex, and baseline lung function levels. Patients who discontinued therapies tended to have higher lung function at the start of ETI (搜索) treatment and were less likely to be infected with Pseudomonas aeruginosa (搜索), a common CF-related lung infection.
ETI (搜索) works by helping the malfunctioning protein that causes CF function more effectively, allowing the lungs to work better from the inside rather than simply treating symptoms like thick mucus or frequent infections. This mechanism of action appears to provide sustained benefits that reduce the need for traditional symptom-management therapies.
Quality of Life Implications
The reduction in treatment burden carries profound implications for quality of life. "For many families, the daily time commitment required for CF care can be overwhelming," Sagel explained. "Seeing people maintain good health while doing fewer respiratory therapies is incredibly encouraging. A reduction in treatment burden can have a profound impact on quality of life."
However, Sagel emphasized the importance of individualized care decisions. "The opportunity to simplify daily treatment is exciting but decisions to stop or continue therapies should be made through shared decision-making with a clinician who understands each person's overall health," he said. The study did not capture individuals' reasons for stopping therapies, highlighting the need for careful clinical oversight.
Future Research Directions
Researchers plan to investigate whether some therapies may still be useful when used only during respiratory illnesses and whether mechanical forms of airway clearance remain necessary for people who no longer depend on inhaled mucus-thinning medications.
"The goal is to help people with CF and their care teams maintain strong long-term health while easing daily treatment demands," said Sagel.
The study was conducted as part of PROMISE, one of the largest long-term projects examining how ETI (搜索) therapy works in everyday care at CF centers across the United States. Additional authors from Seattle Children's Research Institute, the University of Washington, the University of Alabama at Birmingham, the Children's Hospital of Philadelphia, Washington University in St. Louis, and The Hospital for Sick Children (SickKids) in Toronto contributed to the research.